Effects of DHA Supplementation on Hippocampal Volume and Cognitive Function in Older Adults with Mild Cognitive Impairment: A 12-Month Randomized, Double-Blind, Placebo-Controlled Trial.
Effects of DHA Supplementation on Hippocampal Volume and Cognitive Function in Older Adults with Mild Cognitive Impairment: A 12-Month Randomized, Double-Blind, Placebo-Controlled Trial.
复制标题
DOI：
10.3233/jad-160439
复制
发表时间：
2016-11
期刊：
影响因子：
--
通讯作者：
Yan-ping Zhang;Rujuan Miao;Qing Li;Tianfeng Wu;F. Ma
中科院分区：
文献类型：
--
作者：
Yan-ping Zhang;Rujuan Miao;Qing Li;Tianfeng Wu;F. Ma
二十二碳六烯酸 (DHA) 对大脑功能很重要，较高的 DHA 摄入量与阿尔茨海默病的相对风险呈负相关。补充 DHA 对轻度认知障碍 (MCI) 患者的潜在益处尚未得到充分研究。我们的研究旨在确定补充 DHA 对患有 MCI 的老年受试者认知功能和海马萎缩的影响。这是在中国天津进行的一项随机、双盲、安慰剂对照试验。招募了 240 名 65 岁及以上的 MCI 个体，并随机分配到 DHA 组或安慰剂组。参与者接受为期 12 个月的 DHA 补充剂（2 克/天）或玉米油作为安慰剂。在基线、6 个月和 12 个月时测量认知功能和海马体积的整体和特定子域。这两种变化均通过重复测量方差分析 (ANOVA) 进行分析。该试验已注册：ChiCTR-IOR-15006058。共有 219 名参与者（DHA：110，安慰剂：109）完成了试验。与对照组 (+1.06%) 相比，干预组平均血清 DHA 水平的变化更大 (+3.85%)。协方差的重复测量分析表明，在 12 个月内，DHA 治疗组与安慰剂组之间的全量表智商（ηp2 = 0.084；p = 0.039）、信息（ηp2 = 0.439；p = 0.000）和数字跨度（ηp2 = 0.375；p = 0.000）存在显着差异。此外，左侧海马体（ηp2 = 0.121，p = 0.016）、右侧海马体（ηp2 = 0.757，p = 0.008）、总海马体（ηp2 = 0.124，p = 0.023）和整体大脑（ηp2 = 0.145，p = 0.032）两组之间。这些研究结果表明，MCI 受试者补充 DHA（2 克/天）12 个月可以显着改善认知功能并减缓海马萎缩的进展。有必要进行更大规模、更长期的验证性研究。
Docosahexaenoic acid (DHA) is important for brain function, and higher DHA intake is inversely correlated with relative risk of Alzheimer's disease. The potential benefits of DHA supplementation in people with mild cognitive impairment (MCI) have not been fully examined. Our study aimed to determine the effect of DHA supplementation on cognitive function and hippocampal atrophy in elderly subjects with MCI. This was a randomized, double-blind, placebo-controlled trial in Tianjin, China. 240 individuals with MCI aged 65 years and over were recruited and equalized randomly allocated to the DHA or the placebo group. Participants received 12-month DHA supplementation (2 g/day) or corn oil as placebo. Both global and specific subdomains of cognitive function and hippocampal volume were measured at baseline, 6 months, and 12 months. Both changes were analyzed by repeated-measure analysis of variance (ANOVA). This trial has been registered: ChiCTR-IOR-15006058. A total of 219 participants (DHA: 110, Placebo: 109) completed the trial. The change in mean serum DHA levels was greater in the intervention group (+3.85%) compared to the control group (+1.06%). Repeated-measures analyses of covariance showed that, over 12 months, there was a significant difference in the Full-Scale Intelligence Quotient (ηp2 = 0.084; p = 0.039), Information (ηp2 = 0.439; p = 0.000), and Digit Span (ηp2 = 0.375; p = 0.000) between DHA-treated versus the placebo group. In addition, there were significant differences in volumes of left hippocampus (ηp2 = 0.121, p = 0.016), right hippocampus (ηp2 = 0.757, p = 0.008), total hippocampus (ηp2 = 0.124, p = 0.023), and global cerebrum (ηp2 = 0.145, p = 0.032) between the two groups. These findings suggest that DHA supplementation (2 g/day) for 12 months in MCI subjects can significantly improve cognitive function and slow the progression of hippocampal atrophy. Larger, longer-term confirmatory studies are warranted.